Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like ...

CRISPR Therapeutics (NasdaqGM:CRSP ... a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

CRISPR Therapeutics AG (CRSP) has recently been on ... between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, CRISPR Therapeutics is expected ...

Explore CRISPR Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CRSP. CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces market ...

Analysts arrive at stock ratings after doing extensive ... with a price target of $56.00 to $42.00. The current price CRISPR Therapeutics (CRSP) is trading at is $37.79, which is out of the ...

If an investor was to purchase shares of CRSP stock at the current price level of $38.20/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...